Abstract
The role of endotoxin in the genesis of sepsis has long been recognized and multiple treatments aimed at neutralizing it have been studied. Endotoxin can be bound by antibodies (whose role as a therapeutic agent is unlikely), binding proteins such as BPI or human lactoferrin (effectiveness debated and promising respectively) and phospholipid emulsion (which has not improved outcomes in a recent study). Alternatively, the action of endotoxin could be blocked by lipid A analogs (initial study showed no overall benefit and another large trial is near completion targeting a subpopulation of that study). Finally, endotoxin can be bound by polymyxin B embedded in hemoperfusion cartridges. The later treatment has been used for more than a decade in Japan. Since both pre-clinical rationale and studies support the targeting of endotoxin to ameliorate the pro-inflammatory and pro-coagulation response of severe sepsis, this therapeutic intervention is being pursued.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- PAMPs:
-
pathogen-associated molecular patterns
- PRRs:
-
pattern recognition receptors
- IL:
-
interleukin
- TLR:
-
toll-like receptor
- BP:
-
binding protein
- LPS:
-
lipopolysaccharide
- BPI:
-
bactericidal/permeability increasing protein
- HL:
-
human lactoferrin
- PMX B:
-
polymyxin B
- HP:
-
hemoperfusion
- CLP:
-
cecal ligation and perforation
- MAP:
-
mean arterial pressure
References
Angus, D.C., Birmingham, M.C., Balk, R.A., Scannon, P.J., Collins, D., Kruse, J.A., Graham, D.R., Dedhia, H.V., Homann, S., MacIntyre, N. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: A randomized controlled trial. E5 Study Investigators. JAMA 283 (2000) 1723–1730.
Appelmelk, B.J., An, Y.Q., Geerts, M., Thijs, B.G., de Boer, H.A., MacLaren, D.M., de Graaff, J., Nuijens, J.H. Lactoferrin is a lipid A-binding protein. Infect Immun 62 (1994) 2628–2632.
Baumgartner, J.D., Glauser, M.P., McCutchan, J.A., Ziegler, E.J., van Melle, G., Klauber, M.R., Vogt, M., Muehlen, E., Luethy, R., Chiolero, R., et al. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2 (1985) 59–63.
Bhattacharjee, A.K., Opal, S.M., Taylor, R., Naso, R., Semenuk, M., Zollinger, W.D., Moran, E.E., Young, L., Hammack, C., Sadoff, J.C., Cross, A.S. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. J Infect Dis 173 (1996) 1157–1163.
Bone, R.C., Balk, R.A., Fein, A.M., Perl, T.M., Wenzel, R.P., Reines, H.D., Quenzer, R.W., Iberti, T.J., Macintyre, N., Schein, R.M. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 23 (1995) 994–1006.
Bosshart, H., Heinzelmann, M. Targeting bacterial endotoxin: Two sides of a coin. Ann N Y Acad Sci 1096 (2007) 1–17.
Braude, A.I., Jones, J.L., Douglas, H. The behavior of Escherichia coli endotoxin (somatic antigen) during infectious arthritis. J Immunol 90 (1963) 297–311.
Bunnell, E., Lynn, M., Habet, K., Neumann, A., Perdomo, C.A., Friedhoff, L.T., Rogers, S.L. and Parrillo, J.E. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med 28 (2000) 2713–2720.
Calandra, T., Glauser, M.P., Schellekens, J., Verhoef, J. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 158 (1988) 312–319.
Calvano, S.E., Thompson, W.A., Marra, M.N., Coyle, S.M., de Riesthal, H.F., Trousdale, R.K., Barie, P.S., Scott, R.W., Moldawer, L.L., Lowry, S.F. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis. Arch Surg 129 (1994) 220–226.
Cantaluppi, V., Assenzio, B., Pasero, D., Romanazzi, G.M., Pacitti, A., Lanfranco, G., Puntorieri, V., Martin, E.L., Mascia, L., Monti, G., Casella, G., Segoloni, G.P., Camussi, G., Ranieri, V.M. Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 34 (2008) 1638–1645.
Cinel, I., Dellinger, R.P. Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 20 (2007) 345–352.
Cohen, J., Aslam, M., Pusey, C.D., Ryan, C.J. Protection from endotoxemia: A rat model of plasmapheresis and specific adsorption with polymyxin B. J Infect Dis 155 (1987) 690–695.
Cross, A.S., Opal, S.M., Palardy, J.E., Drabick, J.J., Warren, H.S., Huber, C., Cook, P., Bhattacharjee, A.K. Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine 21 (2003) 4576–4587.
Cross, A.S., Opal, S.M., Warren, H.S., Palardy, J.E., Glaser, K., Parejo, N.A., Bhattacharjee, A.K. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J Infect Dis 183 (2001) 1079–1086.
Cruz, D.N., Antonelli, M., Fumagalli, R., Foltran, F., Brienza, N., Donati, A., Malcangi, V., Petrini, F., Volta, G., Bobbio Pallavicini, F.M., Rottoli, F., Giunta, F., Ronco, C. Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial. JAMA 301 (2009) 2445–2452.
Dellinger, R.P., Tomayko, J.F., Angus, D.C., Opal, S., Cupo, M.A., McDermott, S., Ducher, A., Calandra, T., Cohen, J. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 37 (2009) 2929–2938.
Demetriades, D., Smith, J.S., Jacobson, L.E., Moncure, M., Minei, J., Nelson, B.J., Scannon, P.J. Bactericidal/permeability-increasing protein (rBPI21) in patients with hemorrhage due to trauma: Results of a multicenter phase II clinical trial. rBPI21 Acute Hemorrhagic Trauma Study Group. J Trauma 46 (1999) 667–676; discussion 676–677.
Elsbach, P., Weiss, J. The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide. Immunobiology 187 (1993) 417–429.
Elsbach, P., Weiss, J., Doerfler, M., Shu, C., Kohn, F., Ammons, W.S., Kung, A.H., Meszaros, K.K., Parent, J.B. The bactericidal/permeability increasing protein of neutrophils is a potent antibacterial and anti-endotoxin agent in vitro and in vivo. Prog Clin Biol Res 388 (1994) 41–51.
Enomoto, N., Suda, T., Uto, T., Kato, M., Kaida, Y., Ozawa, Y., Miyazaki, H., Kuroishi, S., Hashimoto, D., Naito, T., Fujisawa, T., Matsui, T., Inui, N., Nakamura, Y., Sato, J., Mizuguchi, T., Kato, A., Chida, K. Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia. Respirology 13 (2008) 452–460.
Feingold, K.R., Funk, J.L., Moser, A.H., Shigenaga, J.K., Rapp, J.H., Grunfeld, C. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 63 (1995) 2041–2046.
Fukui, M., Imamura, R., Umemura, M., Kawabe, T., Suda, T. Pathogen-associated molecular patterns sensitize macrophages to Fas ligand-induced apoptosis and IL-1 beta release. J Immunol 171 (2003) 1868–1874.
Giroir, B.P., Scannon, P.J., Levin, M. Bactericidal/permeability-increasing protein--lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia. Crit Care Med 29 (2001) S130–S135.
Goldfarb, R.D., Parker, T.S., Levine, D.M., Glock, D., Akhter, I., Alkhudari, A., McCarthy, R.J., David, E.M., Gordon, B.R., Saal, S.D., Rubin, A.L., Trenholme, G.M., Parrillo, J.E. Protein-free phospholipid emulsion treatment improved cardiopulmonary function and survival in porcine sepsis. Am J Physiol Regul Integr Comp Physiol 284 (2003) R550–R557.
Gordon, B.R., Parker, T.S., Levine, D.M., Saal, S.D., Hudgins, L.C., Sloan, B.J., Chu, C., Stenzel, K.H., Rubin, A.L. Safety and pharmacokinetics of an endotoxin-binding phospholipid emulsion. Ann Pharmacother 37 (2003) 943–950.
Greenman, R.L., Schein, R.M., Martin, M.A., Wenzel, R.P., MacIntyre, N.R., Emmanuel, G., Chmel, H., Kohler, R.B., McCarthy, M., Plouffe, J., et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266 (1991) 1097–1102.
Harris, H.W., Grunfeld, C., Feingold, K.R., Rapp, J.H. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J Clin Invest 86 (1990) 696–702.
Hurley, J.C. Reappraisal with meta-analysis of bacteremia, endotoxemia, and mortality in gram-negative sepsis. J Clin Microbiol 33 (1995) 1278–1282.
Hussein, M.H., Daoud, G.A., Kakita, H., Kato, S., Goto, T., Kamei, M., Goto, K., Ozaki, Y., Ito, T., Fukuda, S., Kato, I., Suzuki, S., Hashimoto, T., Togari, H. Effect of polymyxin B-immobilized fiber hemoperfusion on respiratory impairment, hepatocellular dysfunction, and leucopenia in a neonatal sepsis model. Pediatr Surg Int 26 (2010) 187–193.
Inada, K., Endo, S., Yamashita, H., Suzuki, M., Yoshida, H., Yoshida, M. Inhibitory effect of mouse antiendotoxin monoclonal antibody (E5) on hypotension induced by endotoxin and TNF-alpha. Kansenshogaku Zasshi 67 (1993) 1108–1114.
Ito, M., Kase, H., Shimoyama, O., Takahashi, T. Effects of polymyxin B-immobilized fiber using a rat cecal ligation and perforation model. ASAIO J 55 (2009) 246–250.
Jiang, J., Xie, G., Liu, D., Zhu, P., Wang, Z., He, Y., Zhou, J., Xu, H. Effect of bactericidal /permeability-increasing protein on sepsis induced by intra-abdominal infection in rats. Chin J Traumatol 2 (1999a) 84–86.
Jiang, J., Zhu, P., Wang, Z., Liu, D., He, Y., Xie, G., Xu, H. Protective effects of bactericidal/permeability-increasing protein on the vital organ function after endotoxic shock in rats. Zhonghua Wai Ke Za Zhi 37 (1999b) 120–122.
Kanesaka, S., Sasaki, J., Kuzume, M., Narihara, K., Takahashi, Y. Effect of direct hemoperfusion using polymyxin B immobilized fiber on inflammatory mediators in patients with severe sepsis and septic shock. Int J Artif Organs 31 (2008) 891–897.
Kumar, A., Bunnell, E., Lynn, M., Anel, R., Habet, K., Neumann, A., Parrillo, J.E. Experimental human endotoxemia is associated with depression of load-independent contractility indices: Prevention by the lipid a analogue E5531. Chest 126 (2004) 860–867.
Kushi, H., Miki, T., Nakahara, J., Okamoto, K., Kawahara, Y., Saito, T., Tanjoh, K. Hemoperfusion with an immobilized polymyxin B fiber column improves tissue oxygen metabolism. Ther Apher Dial 10 (2006a) 430–435.
Kushi, H., Miki, T., Nakahara, J., Okamoto, K., Kawahara, Y., Saito, T., Tanjoh, K. Hemoperfusion with an immobilized polymyxin B fiber column reduces circulating interleukin-8 concentrations. Ther Apher Dial 10 (2006b) 425–429.
Kushi, H., Miki, T., Nakahara, J., Okamoto, K., Saito, T., Tanjoh, K. Hemoperfusion with an immobilized polymyxin B column reduces the blood level of neutrophil elastase. Blood Purif 24 (2006c) 212–217.
Kushi, H., Miki, T., Okamaoto, K., Nakahara, J., Saito, T., Tanjoh, K. Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 9 (2005) R653–R661.
Kushi, H., Miki, T., Sakagami, Y., Sato, J., Saito, T., Tanjoh, K. Early hemoperfusion with a polymyxin b column improves gastric intramucosal pH in sepsis. Ther Apher Dial 12 (2008) 278–284.
Levin, M., Quint, P.A., Goldstein, B., Barton, P., Bradley, J.S., Shemie, S.D., Yeh, T., Kim, S.S., Cafaro, D.P., Scannon, P.J., Giroir, B.P. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356 (2000) 961–967.
Levine, D.M., Parker, T.S., Donnelly, T.M., Walsh, A., Rubin, A.L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 90 (1993) 12040–12044.
Levy, O., Martin, S., Eichenwald, E., Ganz, T., Valore, E., Carroll, S.F., Lee, K., Goldmann, D., Thorne, G.M. Impaired innate immunity in the newborn: Newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 104 (1999) 1327–1333.
Lin, W.J., Yeh, W.C. Implication of Toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 24 (2005) 206–209.
Lynn, M., Rossignol, D.P., Wheeler, J.L., Kao, R.J., Perdomo, C.A., Noveck, R., Vargas, R., D'Angelo, T., Gotzkowsky, S., McMahon, F.G. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 187 (2003) 631–639.
Marshall, J.C., Foster, D., Vincent, J.L., Cook, D.J., Cohen, J., Dellinger, R.P., Opal, S., Abraham, E., Brett, S.J., Smith, T., Mehta, S., Derzko, A., Romaschin, A. Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study. J Infect Dis 190 (2004) 527–534.
McCloskey, R.V., Straube, R.C., Sanders, C., Smith, S.M., Smith, C.R. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121 (1994) 1–5.
Mitaka, C., Tsuchida, N., Kawada, K., Nakajima, Y., Imai, T., Sasaki, S. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock. Shock 32 (2009) 478–483.
Morrison, D.C., Jacobs, D.M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 13 (1976) 813–818.
Mullarkey, M., Rose, J.R., Bristol, J., Kawata, T., Kimura, A., Kobayashi, S., Przetak, M., Chow, J., Gusovsky, F., Christ, W.J., Rossignol, D.P. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 304 (2003) 1093–1102.
Nakamura, T., Fujiwara, N., Sato, E., Kawagoe, Y., Ueda, Y., Yamada, S., Koide, H. Effect of polymyxin B-immobilized fiber hemoperfusion on serum high mobility group box-1 protein levels and oxidative stress in patients with acute respiratory distress syndrome. ASAIO J 55 (2009) 395–399.
Nakamura, T., Suzuki, T., Kawagoe, Y., Koide, H. Polymyxin B-immobilized fiber hemoperfusion attenuates increased plasma atrial natriuretic peptide and brain natriuretic Peptide levels in patients with septic shock. ASAIO J 54 (2008) 210–213.
Nemoto, H., Nakamoto, H., Okada, H., Sugahara, S., Moriwaki, K., Arai, M., Kanno, Y., Suzuki, H. Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 19 (2001) 361–368; discussion 368–369.
Noma, S., Matsuyama, W., Mitsuyama, H., Suetsugu, T., Koreeda, Y., Mizuno, K., Higashimoto, I., Kakihana, Y., Hashiguchi, T., Maruyama, I., Osame, M., Arimura, K. Two cases of acute exacerbation of interstitial pneumonia treated with polymyxin B-immobilized fiber column hemoperfusion treatment. Intern Med 46 (2007) 1447–1454.
Oshima, K., Akao, T., Kobayashi, K., Muraoka, M., Matsumoto, K., Takeyoshi, I. The effect of direct hemoperfusion with a polymyxin B-immobilized fiber column (DHP-PMX therapy) on pulmonary ischemia-reperfusion injury in a canine model. J Invest Surg 21 (2008) 127–132.
Parsons, P.E., Worthen, G.S., Moore, E.E., Tate, R.M., Henson, P.M. The association of circulating endotoxin with the development of the adult respiratory distress syndrome. Am Rev Respir Dis 140 (1989) 294–301.
Pollack, M., Huang, A.I., Prescott, R.K., Young, L.S., Hunter, K.W., Cruess, D.F., Tsai, C.M. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest 72 (1983) 1874–1881.
Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. The Intravenous Immunoglobulin Collaborative Study Group. N Engl J Med 327 (1992) 234–240.
Raetz, C.R., Reynolds, C.M., Trent, M.S., Bishop, R.E. Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem 76 (2007) 295–329.
Raetz, C.R., Whitfield, C. Lipopolysaccharide endotoxins. Annu Rev Biochem 71 (2002) 635–700.
Romulo, R.L., Palardy, J.E., Opal, S.M. Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. J Infect Dis 167 (1993) 126–130.
Sato, H., Oshima, K., Arakawa, K., Kobayashi, K., Yamazaki, H., Suto, Y., Takeyoshi, I. Direct hemoperfusion with a polymyxin B-immobilized cartridge in intestinal warm ischemia reperfusion. World J Gastroenterol 14 (2008) 5436–5441.
Sato, H., Oshima, K., Kobayashi, K., Yamazaki, H., Suto, Y., Takeyoshi, I. Hemoperfusion with polymyxin B-immobilized fiber column improves liver function after ischemia-reperfusion injury. World J Gastroenterol 15 (2009) 4571–4575.
Shimizu, T., Hanasawa, K., Sato, K., Umeki, M., Koga, N., Naganuma, T., Sato, S., Shimonishi, T., Ikeda, T., Matsuno, N., Ono, S., Saitoh, H., Satoh, K., Otani, Y., Endo, Y., Eguchi, Y., Tani, T. Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation. Langenbecks Arch Surg 394 (2009) 303–311.
Suyama, H., Kawasaki, Y., Morikawa, S., Kaneko, K., Yamanoue, T. Early induction of PMX-DHP improves oxygenation in severe sepsis patients with acute lung injury. Hiroshima J Med Sci 57 (2008) 79–84.
Taveira da Silva, A.M., Kaulbach, H.C., Chuidian, F.S., Lambert, D.R., Suffredini, A.F., Danner, R.L. Brief report: Shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 328 (1993) 1457–1460.
The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Arch Intern Med 154 (1994) 2484–2491.
Tidswell, M., Tillis, W., Larosa, S.P., Lynn, M., Wittek, A.E., Kao, R., Wheeler, J., Gogate, J., Opal, S.M. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 38 (2010) 72–83.
Townsend, S.R., Schorr, C., Levy, M.M., Dellinger, R.P. Reducing mortality in severe sepsis: The Surviving Sepsis Campaign. Clin Chest Med 29 (2008) 721–733.
Venkatesh, M., Rong, L., Raad, I., Versalovic, J. Novel synergistic antibiofilm combinations for salvage of infected catheters. J Med Microbiol 58 (2009) 936–944.
Venkatesh, M.P., Pham, D., Kong, L., Weisman, L.E. Prophylaxis with lactoferrin, a novel antimicrobial agent, in a neonatal rat model of coinfection. Adv Ther 24 (2007) 941–954.
Venkatesh, M.P., Rong, L. Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative staphylococci and Candida albicans causing neonatal sepsis. J Med Microbiol 57 (2008) 1113–1121.
Volk, H.D., Reinke, P., Krausch, D., Zuckermann, H., Asadullah, K., Muller, J.M., Docke, W.D., Kox, W.J. Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22 Suppl 4 (1996) S474–S481.
Weiss, J., Elsbach, P., Shu, C., Castillo, J., Grinna, L., Horwitz, A., Theofan, G. Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 90 (1992) 1122–1130.
Wu, A., Hinds, C.J., Thiemermann, C. High-density lipoproteins in sepsis and septic shock: Metabolism, actions, and therapeutic applications. Shock 21 (2004) 210–221.
Zeni, F., Freeman, B., Natanson, C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 25 (1997) 1095–1100.
Ziegler, E.J., Fisher, C.J., Jr., Sprung, C.L., Straube, R.C., Sadoff, J.C., Foulke, G.E., Wortel, C.H., Fink, M.P., Dellinger, R.P., Teng, N.N., et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324 (1991) 429–436.
Ziegler, E.J., McCutchan, J.A., Fierer, J., Glauser, M.P., Sadoff, J.C., Douglas, H., Braude, A.I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307 (1982) 1225–1230.
Zinner, S.H., McCabe, W.R. Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. J Infect Dis 133 (1976) 37–45.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Rachoin, JS., Schorr, C.A., Dellinger, R.P. (2010). Targeting Endotoxin in the Treatment of Sepsis. In: Wang, X., Quinn, P. (eds) Endotoxins: Structure, Function and Recognition. Subcellular Biochemistry, vol 53. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9078-2_15
Download citation
DOI: https://doi.org/10.1007/978-90-481-9078-2_15
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9077-5
Online ISBN: 978-90-481-9078-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)